CDR132L
Cross-source consensus on CDR132L from 1 sources and 8 claims.
1 sources · 8 claims
How it works
Benefits
Dosage & preparation
Risks & contraindications
Evidence quality
Highlighted claims
- CDR132L is a synthetic locked nucleic acid antisense oligonucleotide that inhibits microRNA-132. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- CDR132L treatment consisted of three intravenous infusions given 28 days apart at weeks 0, 4, and 8. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- CDR132L was tested at 5 mg kg−1 and 10 mg kg−1 doses against placebo. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- CDR132L did not significantly improve percentage change in LVESVI compared with placebo at 6 months. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- The findings support further clinical investigation of CDR132L but do not establish clinical efficacy. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- CDR132L produced dose-dependent reductions in plasma miR-132, with the largest reductions at 10 mg kg−1. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- CDR132L was well tolerated at both tested doses, with an adverse event profile similar to placebo. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- No renal, hepatic, hematologic, or cardiac toxicity was attributed to CDR132L. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial